[en] This presentation offers a critical appraisal of the EU General Court’s judgment in the Lundbeck case on patent settlments in the pharma industry. It suggests that the European Commission’s approach, which was endorsed by the General Court, fails to adequately balance the various interests at stake, particularly the need to maintain the incentives to innovate that IP aims to foster.
Disciplines :
European & international law Economic & commercial law
Author, co-author :
Hull, David ; Université de Liège - ULiège > Département de droit > Droit international et droit comparé de la concurrence
